IP Library › Granted Patent US 8,618,063
Granted Patent B2
US 8,618,063 · App. 12/099,947 · Granted Dec 31, 2013

Method for treating a synucleinopathy

Inventors: Scott Thomas Brady (Chicago, IL); Gerardo Andres Morfini (Chicago, IL)
Assignee: The Board of Trustees of the University of Illinois
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,618,063
App. No.
12/099,947
Granted
Dec 31, 2013
Kind
B2
Abstract

The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor.

Claims (3)

1. A method for restoring fast axonal transport in a cell which expresses a pathological synuclein protein comprising contacting the cell with an effective amount of an agent that inhibits Protein Kinase C mu or Src-Family Tyrosine Kinase activity and measuring PKC mu or Src-Family Tyrosine Kinase activity, thereby restoring fast axonal transport in the cell, wherein said agent that inhibits Protein Kinase C mu comprises Gö6976, MARCKS peptide, or PKC mu peptide substrate and said agent that inhibits Src-Family Tyrosine Kinase comprises PP2, PP1, Radicicol R2146, Geldanamycin, Herbimycin A, PD173955, SKI-606, or PD162531.

2. A method for treating a synucleinopathy comprising administering to a subject with a synucleinopathy an effective amount of Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor wherein said Protein Kinase C mu inhibitor comprises Gö6976, MARCKS peptide, or PKC mu peptide substrate and said Src-Family Tyrosine Kinase inhibitor comprises PP2, PP1, Radicicol R2146, Geldanamycin, Herbimycin A, PD173955, SKI-606, or PD162531, and measuring PKC mu or Src-Family Tyrosine Kinase activity thereby treating the synucleinopathy.

3. The method of claim 2 , wherein the synucleinopathy is Parkinson's disease.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 18, 2009
From: UNIVERSITY OF ILLINOIS AT CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022276/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2008
From: BRADY, SCOTT THOMAS; MORFINI, GERARDO ANDRES
To: THE BOARD OF TRUSTEES OF THE UNIVERISTY OF ILLINOIS
Reel/Frame 020939/0512 →
Continuity (2)
Related Publication 20090258814A1 · Oct 15, 2009
Related Publication 20100105601A2 · Apr 29, 2010